Drug Profile
Anti-CD73 monoclonal antibody - Bristol Myers Squibb
Alternative Names: Anti-CD73 MAb - Bristol Myers SquibbLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours in USA (Parenteral)
- 10 Jan 2020 Phase-I development is ongoing in USA (Parenteral) (Bristol-Myers Squibb pipeline, January 2020)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Solid tumours in USA